Skip to main content
Nucleic Acids Research logoLink to Nucleic Acids Research
. 1996 Apr 15;24(8):1508–1514. doi: 10.1093/nar/24.8.1508

Oligonucleotide N3'-->P5' phosphoramidates as antisense agents.

S Gryaznov 1, T Skorski 1, C Cucco 1, M Nieborowska-Skorska 1, C Y Chiu 1, D Lloyd 1, J K Chen 1, M Koziolkiewicz 1, B Calabretta 1
PMCID: PMC145826  PMID: 8628685

Abstract

Uniformly modified oligonucleotide N3'-->P5' phosphoramidates, where every 3'-oxygen is replaced by a 3'-amino group, were synthesized. These compounds have very high affinity to single-stranded RNAs and thus have potential utility as antisense agents. As was shown in this study, the oligonucleotide phosphoramidates are resistant to digestion with snake venom phosphodiesterase, to nuclease activity in a HeLa cell nuclear extract, or to nuclease activity in 50% human plasma, where no significant hydrolysis was observed after 8 h. These compounds were used in various in vitro cellular systems as antisense compounds addressed to different targeted regions of c-myb, c-myc and bcr-abl mRNAs. C-myb antisense phosphoramidates at 5 microM caused sequence and dose-dependent inhibition of HL-60 cell proliferation and a 75% reduction in c-myb protein and RNA levels, as determined by Western blot and RT-PCR analysis. Analogous results were observed for anti-c-myc phosphoramidates, where a complete cytostatic effect for HL-60 cells was observed at 1 microM concentration for fully complementary, but not for mismatched compounds, which were indistinguishable from untreated controls. This was correlated with a 93% reduction in c-myc protein level. Moreover, colony formation by the primary CML cells was also inhibited 75-95% and up to 99% by anti-c-myc and anti-bcr-abl phosphoramidate oligonucleotides, respectively, in a sequence- and dose-dependent manner within a 0.5 nM-5 microM dose range. At these concentrations the colony-forming ability of normal bone marrow cells was not affected. The presented in vitro data indicate that oligonucleotide N3'-->P5' phosphoramidates could be used as specific and efficient antisense agents.

Full Text

The Full Text of this article is available as a PDF (106.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bayever E., Iversen P. L., Bishop M. R., Sharp J. G., Tewary H. K., Arneson M. A., Pirruccello S. J., Ruddon R. W., Kessinger A., Zon G. Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. Antisense Res Dev. 1993 Winter;3(4):383–390. doi: 10.1089/ard.1993.3.383. [DOI] [PubMed] [Google Scholar]
  2. Biro S., Fu Y. M., Yu Z. X., Epstein S. E. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):654–658. doi: 10.1073/pnas.90.2.654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brown D. A., Kang S. H., Gryaznov S. M., DeDionisio L., Heidenreich O., Sullivan S., Xu X., Nerenberg M. I. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem. 1994 Oct 28;269(43):26801–26805. [PubMed] [Google Scholar]
  4. Buckheit R. W., Jr, Roberson J. L., Lackman-Smith C., Wyatt J. R., Vickers T. A., Ecker D. J. Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320). AIDS Res Hum Retroviruses. 1994 Nov;10(11):1497–1506. doi: 10.1089/aid.1994.10.1497. [DOI] [PubMed] [Google Scholar]
  5. Caracciolo D., Venturelli D., Valtieri M., Peschle C., Gewirtz A. M., Calabretta B. Stage-related proliferative activity determines c-myb functional requirements during normal human hematopoiesis. J Clin Invest. 1990 Jan;85(1):55–61. doi: 10.1172/JCI114433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chavany C., Connell Y., Neckers L. Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers. Mol Pharmacol. 1995 Oct;48(4):738–746. [PubMed] [Google Scholar]
  7. Chen J. K., Schultz R. G., Lloyd D. H., Gryaznov S. M. Synthesis of oligodeoxyribonucleotide N3'-->P5' phosphoramidates. Nucleic Acids Res. 1995 Jul 25;23(14):2661–2668. doi: 10.1093/nar/23.14.2661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Crooke S. T., Grillone L. R., Tendolkar A., Garrett A., Fratkin M. J., Leeds J., Barr W. H. A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts. Clin Pharmacol Ther. 1994 Dec;56(6 Pt 1):641–646. doi: 10.1038/clpt.1994.189. [DOI] [PubMed] [Google Scholar]
  9. DeDionisio L., Gryaznov S. M. Analysis of a ribonuclease H digestion of N3'-->P5' phosphoramidate-RNA duplexes by capillary gel electrophoresis. J Chromatogr B Biomed Appl. 1995 Jul 7;669(1):125–131. doi: 10.1016/0378-4347(95)00153-a. [DOI] [PubMed] [Google Scholar]
  10. Dean N. M., McKay R., Condon T. P., Bennett C. F. Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem. 1994 Jun 10;269(23):16416–16424. [PubMed] [Google Scholar]
  11. Ding D., Grayaznov S. M., Lloyd D. H., Chandrasekaran S., Yao S., Ratmeyer L., Pan Y., Wilson W. D. An oligodeoxyribonucleotide N3'--> P5' phosphoramidate duplex forms an A-type helix in solution. Nucleic Acids Res. 1996 Jan 15;24(2):354–360. doi: 10.1093/nar/24.2.354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Giles R. V., Tidd D. M. Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures. Nucleic Acids Res. 1992 Feb 25;20(4):763–770. doi: 10.1093/nar/20.4.763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gryaznov S. M., Lloyd D. H., Chen J. K., Schultz R. G., DeDionisio L. A., Ratmeyer L., Wilson W. D. Oligonucleotide N3'-->P5' phosphoramidates. Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5798–5802. doi: 10.1073/pnas.92.13.5798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Guvakova M. A., Yakubov L. A., Vlodavsky I., Tonkinson J. L., Stein C. A. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem. 1995 Feb 10;270(6):2620–2627. doi: 10.1074/jbc.270.6.2620. [DOI] [PubMed] [Google Scholar]
  15. Heikkila R., Schwab G., Wickstrom E., Loke S. L., Pluznik D. H., Watt R., Neckers L. M. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. 1987 Jul 30-Aug 5Nature. 328(6129):445–449. doi: 10.1038/328445a0. [DOI] [PubMed] [Google Scholar]
  16. Holt J. T., Redner R. L., Nienhuis A. W. An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol Cell Biol. 1988 Feb;8(2):963–973. doi: 10.1128/mcb.8.2.963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Inoue H., Hayase Y., Imura A., Iwai S., Miura K., Ohtsuka E. Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides. Nucleic Acids Res. 1987 Aug 11;15(15):6131–6148. doi: 10.1093/nar/15.15.6131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Iribarren A. M., Sproat B. S., Neuner P., Sulston I., Ryder U., Lamond A. I. 2'-O-alkyl oligoribonucleotides as antisense probes. Proc Natl Acad Sci U S A. 1990 Oct;87(19):7747–7751. doi: 10.1073/pnas.87.19.7747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kawasaki A. M., Casper M. D., Freier S. M., Lesnik E. A., Zounes M. C., Cummins L. L., Gonzalez C., Cook P. D. Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J Med Chem. 1993 Apr 2;36(7):831–841. doi: 10.1021/jm00059a007. [DOI] [PubMed] [Google Scholar]
  20. Kibler-Herzog L., Zon G., Uznanski B., Whittier G., Wilson W. D. Duplex stabilities of phosphorothioate, methylphosphonate, and RNA analogs of two DNA 14-mers. Nucleic Acids Res. 1991 Jun 11;19(11):2979–2986. doi: 10.1093/nar/19.11.2979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kimura S., Maekawa T., Hirakawa K., Murakami A., Abe T. Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res. 1995 Mar 15;55(6):1379–1384. [PubMed] [Google Scholar]
  22. Lee C. H., Chen H. H., Hoke G., Jong J. S., White L., Kang Y. H. Antisense gene suppression against human ICAM-1, ELAM-1, and VCAM-1 in cultured human umbilical vein endothelial cells. Shock. 1995 Jul;4(1):1–10. doi: 10.1097/00024382-199507000-00001. [DOI] [PubMed] [Google Scholar]
  23. Marshall W. S., Caruthers M. H. Phosphorodithioate DNA as a potential therapeutic drug. Science. 1993 Mar 12;259(5101):1564–1570. doi: 10.1126/science.7681216. [DOI] [PubMed] [Google Scholar]
  24. Nicolaides N. C., Gualdi R., Casadevall C., Manzella L., Calabretta B. Positive autoregulation of c-myb expression via Myb binding sites in the 5' flanking region of the human c-myb gene. Mol Cell Biol. 1991 Dec;11(12):6166–6176. doi: 10.1128/mcb.11.12.6166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Nielsen P. E., Egholm M., Berg R. H., Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science. 1991 Dec 6;254(5037):1497–1500. doi: 10.1126/science.1962210. [DOI] [PubMed] [Google Scholar]
  26. Skorski T., Kanakaraj P., Nieborowska-Skorska M., Ratajczak M., Szczylik C., Zon G., Arlinghaus R. B., Gewirtz A., Perussia B., Calabretta B. p120 GAP requirement in normal and malignant human hematopoiesis. J Exp Med. 1993 Dec 1;178(6):1923–1933. doi: 10.1084/jem.178.6.1923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Skorski T., Nieborowska-Skorska M., Nicolaides N. C., Szczylik C., Iversen P., Iozzo R. V., Zon G., Calabretta B. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4504–4508. doi: 10.1073/pnas.91.10.4504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Skorski T., Szczylik C., Ratajczak M. Z., Malaguarnera L., Gewirtz A. M., Calabretta B. Growth factor-dependent inhibition of normal hematopoiesis by N-ras antisense oligodeoxynucleotides. J Exp Med. 1992 Mar 1;175(3):743–750. doi: 10.1084/jem.175.3.743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Stein C. A. Does antisense exist? Nat Med. 1995 Nov;1(11):1119–1121. doi: 10.1038/nm1195-1119. [DOI] [PubMed] [Google Scholar]
  30. Szczylik C., Skorski T., Nicolaides N. C., Manzella L., Malaguarnera L., Venturelli D., Gewirtz A. M., Calabretta B. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science. 1991 Aug 2;253(5019):562–565. doi: 10.1126/science.1857987. [DOI] [PubMed] [Google Scholar]
  31. Wilson W. D., Mizan S., Tanious F. A., Yao S., Zon G. The interaction of intercalators and groove-binding agents with DNA triple-helical structures: the influence of ligand structure, DNA backbone modifications and sequence. J Mol Recognit. 1994 Jun;7(2):89–98. doi: 10.1002/jmr.300070206. [DOI] [PubMed] [Google Scholar]
  32. Woolf T. M., Chase J. M., Stinchcomb D. T. Toward the therapeutic editing of mutated RNA sequences. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8298–8302. doi: 10.1073/pnas.92.18.8298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Wyatt J. R., Vickers T. A., Roberson J. L., Buckheit R. W., Jr, Klimkait T., DeBaets E., Davis P. W., Rayner B., Imbach J. L., Ecker D. J. Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1356–1360. doi: 10.1073/pnas.91.4.1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Zhang R., Yan J., Shahinian H. K., Shahinian H., Amin G., Lu Z., Liu T., Saag M. S., Jiang Z., Temsamani J. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther. 1995 Jul;58(1):44–53. doi: 10.1016/0009-9236(95)90071-3. [DOI] [PubMed] [Google Scholar]

Articles from Nucleic Acids Research are provided here courtesy of Oxford University Press

RESOURCES